CellGenix® rh TGF-β1
CellGenix Recombinant Human TGF-β1 reliably promotes the expansion of induced pluripotent stem cells, embryonic stem cellsas well as mesenchymal stem cells. It also stimulates the differentiation of T cells into regulatory T cells and the expansion of regulatory T cells. Proper glycosylation of TGF-ß1 is of significant importance for the protein’s processing and functional expression – one of the reasons why production of this growth factor and certain complexly glycosylated proteins is not feasible using conventional bacterial expression systems.
Transforming Growth Factor-beta 1 (TGF-β1) is a member of the growth factor beta superfamily and plays a role in various cellular functions like cell differentiation, proliferation and apoptosis. It is secreted by most immune cells and especially interacts with T cells, B cells, macrophages and monocytes.
CellGenix Recombinant Human TGF-β1 is produced using a human amniocyte cell line (CAP®). By using the CAP® technology we are able to produce this difficult to express glyco-protein with authentic human post-translational modifications. These human post-translational modifications are not accessible by bacterial expression.
CellGenix® Recombinant Human Transforming Growth Factor-beta 1
CAP® cell line
CellGenix® Preclinical rh TGF-β1
CellGenix® rh TGF-β1
- Preclinical grade – will be further developed to GMP
- The final product contains neither animal- nor human-derived materials
- High activity, purity and product stability
- Differentiation of T cells into regulatory T cells (Treg)
- Expansion of Treg cells
- Expansion of embryonic stem cells (ESCs)
- Expansion of induced pluripotent stem cells (iPSCs)
- Expansion of mesenchymal stem cells (MSCs)
Expressed in CAP® cell line
Human Transforming Growth Factor-beta 1, accession # PO1137, Ala279-Ser390
Lyophilized from a 0.2 µm-filtered solution containing 1% Mannitol
The production cell line was derived from an extensively characterized human amniocyte cell line (CAP®).
|Molecular weight||25.6 kDa|
|Purity||≥ 90%1 as determined by SDS-PAGE|
|Activity||≥ 9 x 106 IU/mg, calibrated against NIBSC #89/514|
|Endotoxin level||< 10 EU/mg|
|Intended use||Intended for preclinical ex vivo use. Not intended for therapeutic use|
1 May contain up to 2% of Insulin-like growth factor-binding protein 2 (IGFBP-2) as a host cell-derived impurity.
Recommended in sterile water to a final concentration of 250 µg/ml.
Ambient temperature. Please refer to Technote to learn more about our shipment validation procedure.
3 years from date of shipment.
Storage & Stability
Store lyophilized cytokine at -20°C to -80°C.
Avoid repeated freeze/thaw cycles.